Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Biallelic loss of BCMA caused a patient with myeloma to relapse after treatment with anti-BCMA CARTcells in the KarMMa trial. Baseline heterozygous BCMA deletions might be a risk factor for treatment resistance immunotherapy MMsm ASH22

) between baseline and relapse across different cell subsets. P-values were calculated using the two-sided wilcoxon rank sum test, no adjustment for multiple comparisons was performed. Horizontal line shows median of expression value. Abbreviations: Th: Helper T cells; Treg: Regulatory T cells; NK: Natural killer cells; Prolif: Proliferating T cells.

Genes with mutations are depicted in red and genes with detected variants of unknown significance . Error bars represent 90 % credible intervals., Total UMI count in non-malignant control cells at baseline vs. progression. We focused on the changes of expression levels from baseline to progression for genes located in the heterozygous deletion region. If the patient acquired the heterozygous deletion after treatment, systematic changes of gene expression are expected in this region.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines